Señales en vivo de EPZM | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 dic 1970 @ 19:00):

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States...

Stats
Volumen de hoy	0.00
Volumen promedio	4.18M
Capitalización de mercado	0.00
EPS	$-0.210 ( 2022-08-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.704
ATR14	$0.0490 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-12	Giordano Michael F	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	13 060	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	3 380 951	Common Stock, par value $0.0001
2022-08-12	Conroy Kevin T	Sell	53 324	Common Stock, par value $0.0001

INSIDER POWER
-89.09
Last 98 transactions
Buy: 31 679 726 \| Sell: 42 571 145

Volumen Correlación

Largo: 0.22 (neutral)

Corto: -0.56 (weak negative)

Signal:(61.298) Neutral

Epizyme Inc Correlación

10 Correlaciones Más Positivas
APOP	0.959
RMRM	0.951
MEIP	0.933
REAL	0.932
PCVX	0.93
NNOX	0.927
TYHT	0.925
CVGI	0.922
JFU	0.921
PRTA	0.921

10 Correlaciones Más Negativas
XMTR	-0.948
ASTR	-0.938
INFI	-0.922
HRZN	-0.922
UPLD	-0.921
DTEA	-0.92
OM	-0.92
VNET	-0.916
LUNG	-0.914
IRWD	-0.913

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Epizyme Inc Correlación - Moneda/Commodity

0.46
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.43
( neutral )

-0.46
( neutral )

Epizyme Inc Finanzas

Annual	2021
Ingresos:	$37.43M
Beneficio Bruto:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2021
Ingresos:	$37.43M
Beneficio Bruto:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2020
Ingresos:	$15.76M
Beneficio Bruto:	$10.70M (67.85 %)
EPS:	$-2.29

FY	2019
Ingresos:	$23.80M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Epizyme Inc

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..